文献速递心脑血管急症

多效药片策略在心血管二级预防中的应用

Polypill Strategy in Secondary Cardiovascular Prevention.
PubMed 文献 · N Engl J Med · 2022-08-26
一句话结论心肌梗死后6个月内使用含阿司匹林、雷米普利和阿托伐他汀的多效药片,较常规治疗显著降低主要不良心血管事件风险(HR 0.76)。

SECURE研究为3期随机对照试验,将2499例心肌梗死后6个月内患者随机分配至多效药片策略组或常规治疗组,多效药片含阿司匹林100 mg、雷米普利2.5/5/10 mg、阿托伐他汀20或40 mg,中位随访36个月。主要复合终点(心血管死亡、非致死性1型心肌梗死、非致死性缺血性卒中或紧急血运重建)发生率多效药片组9.5% vs 常规治疗组12.7%(HR 0.76;95%CI 0.60~0.96;P=0.02)。关键次要终点(心血管死亡、非致死性1型心肌梗死或非致死性缺血性卒中)发生率8.2% vs 11.7%(HR 0.70;95%CI 0.54~0.90;P=0.005)。预设亚组结果一致,患者报告的药物依从性多效药片组更高,不良事件两组相似。

要点

  • 心肌梗死后6个月内使用多效药片(阿司匹林100 mg、雷米普利2.5/5/10 mg、阿托伐他汀20或40 mg)较常规治疗显著降低主要复合终点(9.5% vs 12.7%;HR 0.76;95%CI 0.60~0.96;P=0.02)。
  • 关键次要终点(心血管死亡、非致死性1型心肌梗死或非致死性缺血性卒中)多效药片组8.2% vs 常规治疗组11.7%(HR 0.70;95%CI 0.54~0.90;P=0.005)。
  • 预设亚组结果一致;患者报告的药物依从性多效药片组高于常规治疗组;不良事件两组相似。
  • 中位随访36个月,共2499例患者随机分组(多效药片组1237例,常规治疗组1229例)。

适用人群与场景

  • 心肌梗死后6个月内的患者,随机分配至多效药片策略组或常规治疗组。

处置流程与药物剂量

  • 多效药片治疗由阿司匹林100 mg、雷米普利2.5、5或10 mg、阿托伐他汀20或40 mg组成。

研究设计与关键结果

  • 3期随机对照试验,2499例心肌梗死后6个月内患者随机分配至多效药片策略组(1237例)或常规治疗组(1229例),中位随访36个月。
  • 主要复合终点(心血管死亡、非致死性1型心肌梗死、非致死性缺血性卒中或紧急血运重建)多效药片组118/1237例(9.5%)vs 常规治疗组156/1229例(12.7%)(HR 0.76;95%CI 0.60~0.96;P=0.02)。
  • 关键次要终点(心血管死亡、非致死性1型心肌梗死或非致死性缺血性卒中)多效药片组101例(8.2%)vs 常规治疗组144例(11.7%)(HR 0.70;95%CI 0.54~0.90;P=0.005)。
  • 预设亚组结果一致;患者报告的药物依从性多效药片组高于常规治疗组;不良事件两组相似。

证据类型、等级与局限

  • 证据类型:3期随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,心肌梗死后6个月内使用含阿司匹林、雷米普利和阿托伐他汀的多效药片治疗,较常规治疗显著降低主要不良心血管事件风险。

指南或共识出处

  • SECURE试验(ClinicalTrials.gov注册号NCT02596126;EudraCT注册号2015-002868-17);由欧盟Horizon 2020资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting-enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary prevention of cardiovascular death and complications after myocardial infarction.

METHODS: In this phase 3, randomized, controlled clinical trial, we assigned patients with myocardial infarction within the previous 6 months to a polypill-based strategy or usual care. The polypill treatment consisted of aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg). The primary composite outcome was cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization. The key secondary end point was a composite of cardiovascular death, nonfatal type 1 myocardial infarction, or nonfatal ischemic stroke.

RESULTS: A total of 2499 patients underwent randomization and were followed for a median of 36 months. A primary-outcome event occurred in 118 of 1237 patients (9.5%) in the polypill group and in 156 of 1229 (12.7%) in the usual-care group (hazard ratio, 0.76; 95% confidence interval [CI], 0.60 to 0.96; P = 0.02). A key secondary-outcome event occurred in 101 patients (8.2%) in the polypill group and in 144 (11.7%) in the usual-care group (hazard ratio, 0.70; 95% CI, 0.54 to 0.90; P = 0.005). The results were consistent across prespecified subgroups. Medication adherence as reported by the patients was higher in the polypill group than in the usual-care group. Adverse events were similar between groups.

CONCLUSIONS: Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care. (Funded by the European Union Horizon 2020; SECURE ClinicalTrials.gov number, NCT02596126; EudraCT number, 2015-002868-17.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022. PMID: 36018037. doi:10.1056/NEJMoa2208275

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。